AlterDiag will take full responsibility for the industrialization, regulatory restrictions, and commercialization of the tests.

The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.

The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.

The small Baltimore-based lab is preparing for the possibility of additional appeals as years of litigation wind down.

Quest said that while it will continue to look at acquisition opportunities, it plans to focus on integrating and driving productivity of recently purchased assets.

NEW YORK – Danaher executives said Wednesday that the firm expects the effects from the volume-based procurement program in China and anticipated lower respiratory testing volumes will have an impact ...

While Roche saw a 1 percent decline in full-year 2024 diagnostics sales year over year, the base business within the division rose 8 percent. Overall, Roche reported ...

Life Sciences revenues rose 3 percent year over year to $7.33 billion from $7.14 billion. Diagnostic revenues increased 2 percent to $9.79 billion from $9.58 billion, while Biotechnology revenues ...

The test, which is intended for assessing cardiovascular risk, is the first lipoprotein (a), or Lp(a) test measured in nanomoles per liter to receive FDA clearance.

The €4.5 million ($4.2 million) effort is led by researchers from Sweden's Karolinska Institute and aims to deliver lateral flow tests and point-of-care devices.

For Q1 2025, Danaher said it expects core revenues will decline in the low-single-digit percent range year over year. For full-year 2025, the company anticipates core revenues will increase ...

NEW YORK – Medicare administrative contractors Novitas and First Coast Service Options have postponed the implementation dates of two final local coverage determinations that rescinded coverage for ...